Intarcia Therapeutics Patents

Patent portfolio assigned to Intarcia Therapeutics (verified via public assignee records). Pre-commercial biopharma; lead asset ITCA 650 (exenatide osmotic implant) twice rejected by FDA, assets sold to i2o Therapeutics — never had marketed product, so notable_customers empty. Competitors are GLP-1 makers (Novo Nordisk, Eli Lilly) and implant rival Vivani Medical per Pharmaceutical-Technology / BioWorld. Patents confirmed: Intarcia Therapeutics, Inc. holds a multi-jurisdiction osmotic drug-delivery (Medici) portfolio (Justia patent search).